2021
Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV
Wyse JJ, McGinnis KA, Edelman EJ, Gordon AJ, Manhapra A, Fiellin DA, Moore BA, Korthuis PT, Kennedy AJ, Oldfield BJ, Gaither JR, Gordon KS, Skanderson M, Barry DT, Bryant K, Crystal S, Justice AC, Kraemer KL. Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV. AIDS And Behavior 2021, 26: 975-985. PMID: 34495424, PMCID: PMC8840957, DOI: 10.1007/s10461-021-03452-0.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderVeterans Aging Cohort StudyHIV statusUse disordersOpioid agonist treatmentAging Cohort StudyDiagnosis of HCVTwelve-month retentionPositive health outcomesOAT retentionAgonist therapyCohort studyHIV managementAgonist treatmentPredictors of retentionPatientsHealth outcomesHistory of homelessnessHIVLower likelihoodImproved likelihoodLikelihood of initiationBuprenorphineDisorders
2019
Opioid use trajectory groups and changes in a physical health biomarker among HIV-positive and uninfected patients receiving opioid agonist treatment
McGinnis KA, Fiellin DA, Skanderson M, Hser YI, Lucas GM, Justice AC, Tate JP, Group F. Opioid use trajectory groups and changes in a physical health biomarker among HIV-positive and uninfected patients receiving opioid agonist treatment. Drug And Alcohol Dependence 2019, 204: 107511. PMID: 31546119, PMCID: PMC6993986, DOI: 10.1016/j.drugalcdep.2019.06.014.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentHIV-1 RNADetectable HIV-1 RNAUninfected patientsAgonist treatmentVeterans Aging Cohort StudyResponsiveness of CD4Substance use disorder treatmentHealth effectsUrine toxicology resultsUrine toxicology testsAging Cohort StudyElectronic health record dataUse disorder treatmentHealth record dataPhysical health effectsRace/ethnicityOAT initiationCohort studyOpioid useBiomarker changesToxicology resultsNegative groupUninfected individualsDisorder treatment